Cygnus seeks to use GlucoWatch in children:
This article was originally published in Clinica
Executive Summary
Cygnus has filed a marketing application with the US FDA for permission to expand the use of its noninvasive blood glucose monitor, the GlucoWatch Biographer, to include children with diabetes aged between seven and 17 years. The wristwatch-like device, which was approved in the US for use in adults earlier this year, measures glucose in interstitial fluid every 20 minutes, for up to 12 hours. Cygnus, of Redwood City, California, says that around 13,000 children in the US are diagnosed with diabetes annually.